Pediatric Brain Tumor Foundation
Working to eliminate the challenges of childhood brain tumors

Cure the kids! Give Now

A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma

Study Purpose

This phase III trial studies if selumetinib works just as well as the standard treatment with carboplatin/vincristine (CV) for subjects with NF1-associated low grade glioma (LGG), and to see if selumetinib is better than CV in improving vision in subjects with LGG of the optic pathway (vision nerves). Selumetinib is a drug that works by blocking some enzymes that low-grade glioma tumor cells need for their growth. This results in killing tumor cells. Drugs used as chemotherapy, such as carboplatin and vincristine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether selumetinib works better in treating patients with NF1-associated low-grade glioma compared to standard therapy with carboplatin and vincristine.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 2 Years - 21 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Patients must have a body surface area (BSA) of >= 0.5 m^2 at enrollment.
  • - Patients must have neurofibromatosis type 1 (NF1) based on clinical criteria and/or germline genetic testing.
  • - Patients must be newly diagnosed or have previously diagnosed NF-1 associated LGG that has not been treated with any modality other than surgery.
  • - For patients with optic pathway gliomas (OPGs): - Newly-diagnosed patients with OPG are eligible if there are neurologic symptoms (including visual dysfunction, as defined below) or other exam findings associated with the tumor.
  • - Previously-diagnosed patients with OPG are eligible if they have new or worsening neurologic symptoms (including visual dysfunction, as defined below) or have tumor growth.
  • - For both newly-diagnosed and previously-diagnosed OPG, the patient may be eligible, irrespective of whether there has been tumor growth or other neurological symptoms or worsening, if they meet at least one of the following visual criteria: - Visual worsening, defined as worsening of visual acuity (VA) or visual fields (VF) documented within the past year (by examination or history); OR.
  • - Significant visual dysfunction (defined as VA worse than normal for age by 0.6 logMAR [20/80, 6/24, or 2.5/10] or more in one or both eyes) - For patients with LGG in other locations (i.e., not OPGs): - Newly-diagnosed patients with LGG are eligible if there are neurologic symptoms or other exam findings associated with the tumor.
  • - NOTE: Newly-diagnosed patients with LGG without associated neurologic symptoms or exam findings are not eligible.
  • - Previously-diagnosed patients with LGG are eligible if they have new or worsening neurologic symptoms or have tumor growth.
  • - Although not required, if a biopsy/tumor resection is performed, eligible histologies will include all tumors considered LGG or low-grade astrocytoma (World Health Organization [WHO] grade I and II) by 5th edition WHO classification of central nervous system (CNS) tumors with the exception of subependymal giant cell astrocytoma.
  • - Patients must have two-dimensional measurable tumor >= 1 cm^2.
  • - Patients with metastatic disease or multiple independent primary LGGs are allowed on study.
  • - Creatinine clearance or radioisotope glomerular filtration Rate (GFR) >= 70 mL/min/1.73 m^2 OR a serum creatinine based on age/gender within 7 days prior to enrollment as follows: - Age; maximum serum creatinine (mg/dL) - 2 to < 6 years; 0.8 (male) and 0.8 (female) - 6 to < 10 years; 1 (male) and 1 (female) - 10 to < 13 years; 1.2 (male) and 1.2 (female) - 13 to < 16 years; 1.5 (male) and 1.4 (female) - >= 16 years; 1.7 (male) and 1.4 (female) - Total bilirubin =< 1.5 x upper limit of normal (ULN) for age within 7 days prior to enrollment (children with a diagnosis of Gilbert's syndrome will be allowed on study regardless of their total and indirect [unconjugated] bilirubin levels as long as their direct [conjugated] bilirubin is < 3.1 mg/dL) - Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 3 x upper limit of normal (ULN) = 135 U/L within 7 days prior to enrollment.
For the purpose of this study, the ULN for SGPT is 45 U/L.
  • - Albumin >= 2 g/dL within 7 days prior to enrollment.
  • - Left ventricular ejection fraction (LVEF) >= 53% (or institutional normal; if the LVEF result is given as a range of values, then the upper value of the range will be used) by echocardiogram within 7 days prior to enrollment.
  • - Corrected QT (QTc) interval =< 450 msec by electrocardiography (EKG) within 7 days prior to enrollment.
  • - Absolute neutrophil count >= 1,000/uL (unsupported) within 7 days prior to enrollment.
  • - Platelets >= 100,000/uL (unsupported) within 7 days prior to enrollment.
  • - Hemoglobin >= 8 g/dL (may be supported) within 7 days prior to enrollment.
  • - Patients with a known seizure disorder should be stable and should have not experienced a significant increase in seizure frequency within 2 weeks prior to enrollment.
  • - Patients 2-17 years of age must have a blood pressure that is =< 95th percentile for age, height, and gender at the time of enrollment.
Patients >= 18 years of age must have a blood pressure =< 130/80 mmHg at the time of enrollment (with or without the use of antihypertensive medications).
  • - Note: Adequate blood pressure can be achieved using medication for the treatment of hypertension.
  • - All patients must have ophthalmology toxicity assessments performed within 4 weeks prior to enrollment.
  • - For all patients, an MRI of the brain (with orbital cuts for optic pathway tumors) and/or spine (depending on the site(s) of primary disease) with and without contrast must be performed within 4 weeks prior to enrollment.
  • - For patients who undergo a surgery on the target tumor (not required), a pre- and post-operative* MRI of the brain (with orbital cuts for optic pathway tumors) or spine (depending on the site(s) of primary disease) with and without contrast must also be performed within 4 weeks prior to enrollment.
  • - The post-operative MRIs should be performed ideally within 48 hours after surgery if possible.
  • - Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, or 2.
Use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age.
  • - Patients must have the ability to swallow whole capsules.
  • - Patients must have receptive and expressive language skills in English or Spanish to complete the quality of life (QOL) and neurocognitive assessments.
  • - All patients and/or their parents or legal guardians must sign a written informed consent.
  • - All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met.

Exclusion Criteria:

  • - Patients must not have received any prior tumor-directed therapy including chemotherapy, radiation therapy, immunotherapy, or bone marrow transplant.
Prior surgical intervention is permitted.
  • - Patients with a concurrent malignancy or history of treatment (other than surgery) for another tumor within the last year are ineligible.
  • - Patients may not be receiving any other investigational agents.
  • - Patients with any serious medical or psychiatric illness/ condition, including substance use disorders likely in the judgement of the investigator to interfere or limit compliance with study requirements/treatment are not eligible.
  • - Patients who, in the opinion of the investigator, are not able to comply with the study procedures are not eligible.
  • - Female patients who are pregnant are not eligible since fetal toxicities and teratogenic effects have been noted for several of the study drugs.
A pregnancy test is required for female patients of childbearing potential.
  • - Lactating females who plan to breastfeed their infants are not eligible.
  • - Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation and for 12 weeks after stopping study therapy are not eligible.
  • - Note: Women of child-bearing potential and males with sexual partners who are pregnant or who could become pregnant (i.e., women of child-bearing potential) should use effective methods of contraception for the duration of the study and for 12 weeks after stopping study therapy to avoid pregnancy and/or potential adverse effects on the developing embryo.
  • - Cardiac conditions: - Known genetic disorder that increases risk for coronary artery disease.
Note: The presence of dyslipidemia in a family with a history of myocardial infarction is not in itself an exclusion unless there is a known genetic disorder documented.
  • - Symptomatic heart failure.
  • - New York Heart Association (NYHA) class II-IV prior or current cardiomyopathy.
  • - Severe valvular heart disease.
  • - History of atrial fibrillation.
  • - Ophthalmologic conditions: - Current or past history of central serous retinopathy.
  • - Current or past history of retinal vein occlusion or retinal detachment.
  • - Patients with uncontrolled glaucoma.
  • - If checking pressure is clinically indicated, patients with intraocular pressure (IOP) > 22 mmHg or ULN adjusted by age are not eligible.
  • - Ophthalmological findings secondary to long-standing optic pathway glioma (such as visual loss, optic nerve pallor, or strabismus) or longstanding orbito-temporal plexiform neurofibroma (PN, such as visual loss, strabismus) will NOT be considered a significant abnormality for the purposes of the study.
  • - Treatments and/or medications patient is receiving that would make her/him ineligible, such as: - Supplementation with vitamin E greater than 100% of the daily recommended dose.
Any multivitamin containing vitamin E must be stopped prior to study enrollment even if less than 100% of the daily recommended dosing for vitamin E.
  • - Surgery within 2 weeks prior to enrollment, with the exception of surgical placement for vascular access or cerebrospinal fluid (CSF) diverting procedures such as endoscopic third ventriculostomy (ETV) and ventriculo-peritoneal (VP) shunt.
  • - Note: Patients must have healed from any prior surgery prior to enrollment.
- Patients who have an uncontrolled infection are not eligible

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT03871257
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 3
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

National Cancer Institute (NCI)
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Jason R Fangusaro
Principal Investigator Affiliation Children's Oncology Group
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

NIH
Overall Status Recruiting
Countries Canada, Puerto Rico, United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Low Grade Glioma, Neurofibromatosis Type 1, Visual Pathway Glioma
Additional Details

PRIMARY OBJECTIVES:

  • I. To determine whether the efficacy of treatment with selumetinib sulfate (selumetinib) as measured by event-free survival (EFS) is non-inferior to treatment with carboplatin/vincristine sulfate (vincristine) (CV) in previously untreated neurofibromatosis type 1 (NF1)-associated low-grade glioma (LGG).
  • II. To determine whether visual acuity (VA) using Teller acuity cards (TAC), in patients with NF1-associated LGG within the optic pathway, is better in those treated with selumetinib compared to CV.
SECONDARY OBJECTIVES:
  • I. To estimate tumor response rates and overall survival (OS) in each treatment regimen in previously untreated NF1-associated LGG.
  • II. To evaluate VA outcomes utilizing HOTV letter acuity testing in previously untreated NF1-associated LGG within the optic pathway in patients who are old enough to perform visual acuity testing utilizing HOTV (a recognition acuity measure).
  • III. To describe the improvement in motor function as measured by the Vineland scale in patients with previously untreated NF1-associated LGG that have documented motor deficits at enrollment.
  • IV. To prospectively evaluate and compare the quality of life among patients treated with selumetinib or CV.
  • V. To prospectively evaluate and compare the cognitive, social, emotional, and behavioral functioning of patients with NF1-associated LGG treated with either selumetinib or CV.
EXPLORATORY OBJECTIVES:
  • I. To evaluate optical coherence tomography (OCT) measures of retinal axon and ganglion cell thickness as a marker of treatment response in previously untreated NF1-associated LGG within the optic pathway.
  • II. To compare novel, semi-automated volumetric magnetic resonance imaging (MRI) measures to traditional measurements of treatment response (bi-dimensional MRI measurements) in NF1-associated optic pathway tumors.
  • III. To obtain paired blood and tumor tissue to be banked for future NF1-LGG biology studies involving comprehensive molecular analysis, including but not limited to whole exome and ribonucleic acid (RNA) sequencing.
OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: INDUCTION: Patients receive carboplatin intravenously (IV) over 60 minutes on days 1, 8, 15, 22, 43, 50, 57, and 64 and vincristine IV or IV push over 1 minute on days 1, 8, 15, 22, 29, 36, 43, 50, 57, and 64 in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Patients receive carboplatin IV over 60 minutes on days 1, 8, 15, and 22 and vincristine IV or IV push over 1 minute on days 1, 8, and 15. Treatment repeats every 6 weeks for 8 cycles in the absence of disease progression or unacceptable toxicity. ARM II: Patients receive selumetinib sulfate orally (PO) twice daily (BID) on days 1-28. Treatment is continuous and repeats every 28 days for 27 cycles in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up with MRIs and physical exams every 3 months for 1 year, every 6 months for 2 years, and then once yearly for up to 10 years.

Arms & Interventions

Arms

Active Comparator: Arm I (carboplatin, vincristine)

INDUCTION: Patients receive carboplatin IV over 60 minutes on days 1, 8, 15, 22, 43, 50, 57, and 64 and vincristine IV or IV push over 1 minute on days 1, 8, 15, 22, 29, 36, 43, 50, 57, and 64 in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Patients receive carboplatin IV over 60 minutes on days 1, 8, 15, and 22 and vincristine IV or IV push over 1 minute on days 1, 8, and 15. Treatment repeats every 6 weeks for 8 cycles in the absence of disease progression or unacceptable toxicity.

Experimental: Arm II (selumetinib sulfate)

Patients receive selumetinib sulfate PO BID on days 1-28. Treatment is continuous and repeats every 28 days for 27 cycles in the absence of disease progression or unacceptable toxicity.

Interventions

Drug: - Carboplatin

Given IV

Other: - Quality-of-Life Assessment

Ancillary studies

Other: - Questionnaire Administration

Ancillary studies

Drug: - Selumetinib Sulfate

Given PO

Drug: - Vincristine Sulfate

Given IV or IV push

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Children's Hospital of Alabama, Birmingham, Alabama

Status

Recruiting

Address

Children's Hospital of Alabama

Birmingham, Alabama, 35233

Site Contact

Site Public Contact

oncologyresearch@peds.uab.edu

205-638-9285

Banner Children's at Desert, Mesa, Arizona

Status

Recruiting

Address

Banner Children's at Desert

Mesa, Arizona, 85202

Site Contact

Site Public Contact

480-412-3100

Phoenix Childrens Hospital, Phoenix, Arizona

Status

Recruiting

Address

Phoenix Childrens Hospital

Phoenix, Arizona, 85016

Site Contact

Site Public Contact

602-546-0920

Arkansas Children's Hospital, Little Rock, Arkansas

Status

Recruiting

Address

Arkansas Children's Hospital

Little Rock, Arkansas, 72202-3591

Site Contact

Site Public Contact

501-364-7373

Loma Linda University Medical Center, Loma Linda, California

Status

Recruiting

Address

Loma Linda University Medical Center

Loma Linda, California, 92354

Site Contact

Site Public Contact

909-558-4050

Children's Hospital Los Angeles, Los Angeles, California

Status

Recruiting

Address

Children's Hospital Los Angeles

Los Angeles, California, 90027

Site Contact

Site Public Contact

323-361-4110

Kaiser Permanente-Oakland, Oakland, California

Status

Recruiting

Address

Kaiser Permanente-Oakland

Oakland, California, 94611

Site Contact

Site Public Contact

Kpoct@kp.org

877-642-4691

UCSF Medical Center-Mission Bay, San Francisco, California

Status

Recruiting

Address

UCSF Medical Center-Mission Bay

San Francisco, California, 94158

Site Contact

Site Public Contact

877-827-3222

Children's Hospital Colorado, Aurora, Colorado

Status

Recruiting

Address

Children's Hospital Colorado

Aurora, Colorado, 80045

Site Contact

Site Public Contact

josh.b.gordon@nsmtp.kp.org

303-764-5056

Connecticut Children's Medical Center, Hartford, Connecticut

Status

Recruiting

Address

Connecticut Children's Medical Center

Hartford, Connecticut, 06106

Site Contact

Site Public Contact

860-545-9981

Alfred I duPont Hospital for Children, Wilmington, Delaware

Status

Recruiting

Address

Alfred I duPont Hospital for Children

Wilmington, Delaware, 19803

Site Contact

Site Public Contact

dperry@nemours.org

302-651-6884

Children's National Medical Center, Washington, District of Columbia

Status

Recruiting

Address

Children's National Medical Center

Washington, District of Columbia, 20010

Site Contact

Site Public Contact

202-884-2549

Gainesville, Florida

Status

Recruiting

Address

University of Florida Health Science Center - Gainesville

Gainesville, Florida, 32610

Site Contact

Site Public Contact

cancer-center@ufl.edu

352-273-8010

Hollywood, Florida

Status

Recruiting

Address

Memorial Regional Hospital/Joe DiMaggio Children's Hospital

Hollywood, Florida, 33021

Site Contact

Site Public Contact

OHR@mhs.net

954-265-1847

Nemours Children's Clinic-Jacksonville, Jacksonville, Florida

Status

Recruiting

Address

Nemours Children's Clinic-Jacksonville

Jacksonville, Florida, 32207

Site Contact

Site Public Contact

904-697-3529

Nicklaus Children's Hospital, Miami, Florida

Status

Recruiting

Address

Nicklaus Children's Hospital

Miami, Florida, 33155

Site Contact

Site Public Contact

888-624-2778

AdventHealth Orlando, Orlando, Florida

Status

Recruiting

Address

AdventHealth Orlando

Orlando, Florida, 32803

Site Contact

Site Public Contact

FH.Cancer.Research@flhosp.org

407-303-2090

Arnold Palmer Hospital for Children, Orlando, Florida

Status

Recruiting

Address

Arnold Palmer Hospital for Children

Orlando, Florida, 32806

Site Contact

Site Public Contact

melissa.leffin@orlandohealth.com

321-841-2008

Johns Hopkins All Children's Hospital, Saint Petersburg, Florida

Status

Suspended

Address

Johns Hopkins All Children's Hospital

Saint Petersburg, Florida, 33701

Atlanta, Georgia

Status

Recruiting

Address

Children's Healthcare of Atlanta - Egleston

Atlanta, Georgia, 30322

Site Contact

Site Public Contact

Leann.Schilling@choa.org

404-785-2025

Honolulu, Hawaii

Status

Recruiting

Address

Kapiolani Medical Center for Women and Children

Honolulu, Hawaii, 96826

Site Contact

Site Public Contact

808-983-6090

Saint Luke's Cancer Institute - Boise, Boise, Idaho

Status

Recruiting

Address

Saint Luke's Cancer Institute - Boise

Boise, Idaho, 83712

Site Contact

Site Public Contact

eslinget@slhs.org

208-381-2774

Lurie Children's Hospital-Chicago, Chicago, Illinois

Status

Recruiting

Address

Lurie Children's Hospital-Chicago

Chicago, Illinois, 60611

Site Contact

Site Public Contact

773-880-4562

Chicago, Illinois

Status

Recruiting

Address

University of Chicago Comprehensive Cancer Center

Chicago, Illinois, 60637

Site Contact

Site Public Contact

cancerclinicaltrials@bsd.uchicago.edu

773-702-8222

Springfield, Illinois

Status

Recruiting

Address

Southern Illinois University School of Medicine

Springfield, Illinois, 62702

Site Contact

Site Public Contact

217-545-7929

Riley Hospital for Children, Indianapolis, Indiana

Status

Recruiting

Address

Riley Hospital for Children

Indianapolis, Indiana, 46202

Site Contact

Site Public Contact

800-248-1199

Indianapolis, Indiana

Status

Recruiting

Address

Saint Vincent Hospital and Health Care Center

Indianapolis, Indiana, 46260

Site Contact

Site Public Contact

research@stvincent.org

317-338-2194

Blank Children's Hospital, Des Moines, Iowa

Status

Recruiting

Address

Blank Children's Hospital

Des Moines, Iowa, 50309

Site Contact

Site Public Contact

samantha.mallory@unitypoint.org

515-241-8912

Iowa City, Iowa

Status

Recruiting

Address

University of Iowa/Holden Comprehensive Cancer Center

Iowa City, Iowa, 52242

Site Contact

Site Public Contact

800-237-1225

Lexington, Kentucky

Status

Recruiting

Address

University of Kentucky/Markey Cancer Center

Lexington, Kentucky, 40536

Site Contact

Site Public Contact

859-257-3379

Norton Children's Hospital, Louisville, Kentucky

Status

Recruiting

Address

Norton Children's Hospital

Louisville, Kentucky, 40202

Site Contact

Site Public Contact

CancerResource@nortonhealthcare.org

502-629-5500

Children's Hospital New Orleans, New Orleans, Louisiana

Status

Recruiting

Address

Children's Hospital New Orleans

New Orleans, Louisiana, 70118

Site Contact

Site Public Contact

CHResearch@lcmchealth.org

Eastern Maine Medical Center, Bangor, Maine

Status

Recruiting

Address

Eastern Maine Medical Center

Bangor, Maine, 04401

Site Contact

Site Public Contact

207-973-4274

Maine Children's Cancer Program, Scarborough, Maine

Status

Recruiting

Address

Maine Children's Cancer Program

Scarborough, Maine, 04074

Site Contact

Site Public Contact

sverwys@mmc.org

207-396-7581

Baltimore, Maryland

Status

Recruiting

Address

Johns Hopkins University/Sidney Kimmel Cancer Center

Baltimore, Maryland, 21287

Site Contact

Site Public Contact

jhcccro@jhmi.edu

410-955-8804

Boston, Massachusetts

Status

Recruiting

Address

Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02114

Site Contact

Site Public Contact

877-726-5130

Dana-Farber Cancer Institute, Boston, Massachusetts

Status

Recruiting

Address

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215

Site Contact

Site Public Contact

877-442-3324

C S Mott Children's Hospital, Ann Arbor, Michigan

Status

Recruiting

Address

C S Mott Children's Hospital

Ann Arbor, Michigan, 48109

Site Contact

Site Public Contact

800-865-1125

Detroit, Michigan

Status

Recruiting

Address

Wayne State University/Karmanos Cancer Institute

Detroit, Michigan, 48201

Site Contact

Site Public Contact

ctoadmin@karmanos.org

313-576-9790

Grand Rapids, Michigan

Status

Recruiting

Address

Helen DeVos Children's Hospital at Spectrum Health

Grand Rapids, Michigan, 49503

Site Contact

Site Public Contact

crcwm-regulatory@crcwm.org

616-391-1230

Minneapolis, Minnesota

Status

Recruiting

Address

Children's Hospitals and Clinics of Minnesota - Minneapolis

Minneapolis, Minnesota, 55404

Site Contact

Site Public Contact

612-813-5193

Minneapolis, Minnesota

Status

Recruiting

Address

University of Minnesota/Masonic Cancer Center

Minneapolis, Minnesota, 55455

Site Contact

Site Public Contact

612-624-2620

Mayo Clinic in Rochester, Rochester, Minnesota

Status

Recruiting

Address

Mayo Clinic in Rochester

Rochester, Minnesota, 55905

Site Contact

Site Public Contact

855-776-0015

University of Mississippi Medical Center, Jackson, Mississippi

Status

Recruiting

Address

University of Mississippi Medical Center

Jackson, Mississippi, 39216

Site Contact

Site Public Contact

601-815-6700

Columbia Regional, Columbia, Missouri

Status

Recruiting

Address

Columbia Regional

Columbia, Missouri, 65201

Site Contact

Site Public Contact

helpdesk@childrensoncologygroup.org

Children's Mercy Hospitals and Clinics, Kansas City, Missouri

Status

Recruiting

Address

Children's Mercy Hospitals and Clinics

Kansas City, Missouri, 64108

Site Contact

Site Public Contact

rryan@cmh.edu

816-302-6808

Saint Louis, Missouri

Status

Recruiting

Address

Cardinal Glennon Children's Medical Center

Saint Louis, Missouri, 63104

Site Contact

Site Public Contact

314-268-4000

Washington University School of Medicine, Saint Louis, Missouri

Status

Recruiting

Address

Washington University School of Medicine

Saint Louis, Missouri, 63110

Site Contact

Site Public Contact

info@siteman.wustl.edu

800-600-3606

Omaha, Nebraska

Status

Recruiting

Address

Children's Hospital and Medical Center of Omaha

Omaha, Nebraska, 68114

Site Contact

Site Public Contact

402-955-3949

University of Nebraska Medical Center, Omaha, Nebraska

Status

Recruiting

Address

University of Nebraska Medical Center

Omaha, Nebraska, 68198

Site Contact

Site Public Contact

unmcrsa@unmc.edu

402-559-6941

Morristown Medical Center, Morristown, New Jersey

Status

Recruiting

Address

Morristown Medical Center

Morristown, New Jersey, 07960

Site Contact

Site Public Contact

973-971-5900

New Brunswick, New Jersey

Status

Recruiting

Address

Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital

New Brunswick, New Jersey, 08903

Site Contact

Site Public Contact

732-235-8675

University of New Mexico Cancer Center, Albuquerque, New Mexico

Status

Suspended

Address

University of New Mexico Cancer Center

Albuquerque, New Mexico, 87102

Albany Medical Center, Albany, New York

Status

Recruiting

Address

Albany Medical Center

Albany, New York, 12208

Site Contact

Site Public Contact

518-262-5513

Roswell Park Cancer Institute, Buffalo, New York

Status

Recruiting

Address

Roswell Park Cancer Institute

Buffalo, New York, 14263

Site Contact

Site Public Contact

askroswell@roswellpark.org

800-767-9355

New York, New York

Status

Recruiting

Address

Laura and Isaac Perlmutter Cancer Center at NYU Langone

New York, New York, 10016

Site Contact

Site Public Contact

CancerTrials@nyulangone.org

Memorial Sloan Kettering Cancer Center, New York, New York

Status

Recruiting

Address

Memorial Sloan Kettering Cancer Center

New York, New York, 10065

Site Contact

Site Public Contact

212-639-7592

Charlotte, North Carolina

Status

Recruiting

Address

Carolinas Medical Center/Levine Cancer Institute

Charlotte, North Carolina, 28203

Site Contact

Site Public Contact

800-804-9376

Duke University Medical Center, Durham, North Carolina

Status

Recruiting

Address

Duke University Medical Center

Durham, North Carolina, 27710

Site Contact

Site Public Contact

888-275-3853

East Carolina University, Greenville, North Carolina

Status

Recruiting

Address

East Carolina University

Greenville, North Carolina, 27834

Site Contact

Site Public Contact

eubankss@ecu.edu

252-744-1015

Wake Forest University Health Sciences, Winston-Salem, North Carolina

Status

Recruiting

Address

Wake Forest University Health Sciences

Winston-Salem, North Carolina, 27157

Site Contact

Site Public Contact

336-713-6771

Sanford Broadway Medical Center, Fargo, North Dakota

Status

Recruiting

Address

Sanford Broadway Medical Center

Fargo, North Dakota, 58122

Akron, Ohio

Status

Recruiting

Address

Children's Hospital Medical Center of Akron

Akron, Ohio, 44308

Site Contact

Site Public Contact

330-543-3193

Cincinnati, Ohio

Status

Recruiting

Address

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, 45229

Site Contact

Site Public Contact

cancer@cchmc.org

513-636-2799

Rainbow Babies and Childrens Hospital, Cleveland, Ohio

Status

Recruiting

Address

Rainbow Babies and Childrens Hospital

Cleveland, Ohio, 44106

Site Contact

Site Public Contact

216-844-5437

Nationwide Children's Hospital, Columbus, Ohio

Status

Recruiting

Address

Nationwide Children's Hospital

Columbus, Ohio, 43205

Site Contact

Site Public Contact

amy.yekisa@nationwidechildrens.org

614-072-2657

Dayton Children's Hospital, Dayton, Ohio

Status

Recruiting

Address

Dayton Children's Hospital

Dayton, Ohio, 45404

Site Contact

Site Public Contact

800-228-4055

Oklahoma City, Oklahoma

Status

Recruiting

Address

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104

Site Contact

Site Public Contact

ou-clinical-trials@ouhsc.edu

405-271-8777

Legacy Emanuel Children's Hospital, Portland, Oregon

Status

Recruiting

Address

Legacy Emanuel Children's Hospital

Portland, Oregon, 97227

Site Contact

Site Public Contact

503-413-2560

Oregon Health and Science University, Portland, Oregon

Status

Recruiting

Address

Oregon Health and Science University

Portland, Oregon, 97239

Site Contact

Site Public Contact

trials@ohsu.edu

503-494-1080

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

Status

Recruiting

Address

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104

Site Contact

Site Public Contact

CancerTrials@email.chop.edu

267-425-5544

Pittsburgh, Pennsylvania

Status

Recruiting

Address

Children's Hospital of Pittsburgh of UPMC

Pittsburgh, Pennsylvania, 15224

Site Contact

Site Public Contact

jean.tersak@chp.edu

412-692-8570

Rhode Island Hospital, Providence, Rhode Island

Status

Recruiting

Address

Rhode Island Hospital

Providence, Rhode Island, 02903

Site Contact

Site Public Contact

401-444-1488

BI-LO Charities Children's Cancer Center, Greenville, South Carolina

Status

Recruiting

Address

BI-LO Charities Children's Cancer Center

Greenville, South Carolina, 29605

Site Contact

Site Public Contact

864-241-6251

East Tennessee Childrens Hospital, Knoxville, Tennessee

Status

Recruiting

Address

East Tennessee Childrens Hospital

Knoxville, Tennessee, 37916

Site Contact

Site Public Contact

865-541-8266

Saint Jude Children's Research Hospital, Memphis, Tennessee

Status

Recruiting

Address

Saint Jude Children's Research Hospital

Memphis, Tennessee, 38105

Site Contact

Site Public Contact

referralinfo@stjude.org

888-226-4343

Nashville, Tennessee

Status

Recruiting

Address

Vanderbilt University/Ingram Cancer Center

Nashville, Tennessee, 37232

Site Contact

Site Public Contact

800-811-8480

Austin, Texas

Status

Recruiting

Address

Dell Children's Medical Center of Central Texas

Austin, Texas, 78723

Site Contact

Site Public Contact

TXAUS-DL-SFCHemonc.research@ascension.org

512-628-1902

Dallas, Texas

Status

Recruiting

Address

UT Southwestern/Simmons Cancer Center-Dallas

Dallas, Texas, 75390

Site Contact

Site Public Contact

canceranswerline@UTSouthwestern.edu

214-648-7097

El Paso Children's Hospital, El Paso, Texas

Status

Recruiting

Address

El Paso Children's Hospital

El Paso, Texas, 79905

Site Contact

Site Public Contact

ranjan.bista@ttuhsc.edu

915-298-5444

Cook Children's Medical Center, Fort Worth, Texas

Status

Recruiting

Address

Cook Children's Medical Center

Fort Worth, Texas, 76104

Site Contact

Site Public Contact

CookChildrensResearch@cookchildrens.org

682-885-2103

Houston, Texas

Status

Recruiting

Address

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center

Houston, Texas, 77030

Site Contact

Site Public Contact

burton@bcm.edu

713-798-1354

M D Anderson Cancer Center, Houston, Texas

Status

Suspended

Address

M D Anderson Cancer Center

Houston, Texas, 77030

Covenant Children's Hospital, Lubbock, Texas

Status

Recruiting

Address

Covenant Children's Hospital

Lubbock, Texas, 79410

Site Contact

Site Public Contact

helpdesk@childrensoncologygroup.org

UMC Cancer Center / UMC Health System, Lubbock, Texas

Status

Recruiting

Address

UMC Cancer Center / UMC Health System

Lubbock, Texas, 79415

Site Contact

Site Public Contact

806-775-8590

Children's Hospital of San Antonio, San Antonio, Texas

Status

Recruiting

Address

Children's Hospital of San Antonio

San Antonio, Texas, 78207

Site Contact

Site Public Contact

helpdesk@childrensoncologygroup.org

San Antonio, Texas

Status

Recruiting

Address

Methodist Children's Hospital of South Texas

San Antonio, Texas, 78229

Site Contact

Site Public Contact

Vinod.GidvaniDiaz@hcahealthcare.com

210-575-6240

San Antonio, Texas

Status

Recruiting

Address

University of Texas Health Science Center at San Antonio

San Antonio, Texas, 78229

Site Contact

Site Public Contact

phoresearchoffice@uthscsa.edu

210-450-3800

Primary Children's Hospital, Salt Lake City, Utah

Status

Recruiting

Address

Primary Children's Hospital

Salt Lake City, Utah, 84113

Site Contact

Site Public Contact

801-585-5270

Norfolk, Virginia

Status

Recruiting

Address

Children's Hospital of The King's Daughters

Norfolk, Virginia, 23507

Site Contact

Site Public Contact

CCBDCresearch@chkd.org

757-668-7243

Richmond, Virginia

Status

Recruiting

Address

Virginia Commonwealth University/Massey Cancer Center

Richmond, Virginia, 23298

Site Contact

Site Public Contact

CTOclinops@vcu.edu

Seattle Children's Hospital, Seattle, Washington

Status

Recruiting

Address

Seattle Children's Hospital

Seattle, Washington, 98105

Site Contact

Site Public Contact

866-987-2000

Spokane, Washington

Status

Recruiting

Address

Providence Sacred Heart Medical Center and Children's Hospital

Spokane, Washington, 99204

Site Contact

Site Public Contact

HopeBeginsHere@providence.org

800-228-6618

Tacoma, Washington

Status

Recruiting

Address

Mary Bridge Children's Hospital and Health Center

Tacoma, Washington, 98405

Site Contact

Site Public Contact

research@multicare.org

253-403-1461

Madigan Army Medical Center, Tacoma, Washington

Status

Recruiting

Address

Madigan Army Medical Center

Tacoma, Washington, 98431

Site Contact

Site Public Contact

mamcdci@amedd.army.mil

253-968-0129

Madison, Wisconsin

Status

Recruiting

Address

University of Wisconsin Hospital and Clinics

Madison, Wisconsin, 53792

Site Contact

Site Public Contact

800-622-8922

Children's Hospital of Wisconsin, Milwaukee, Wisconsin

Status

Recruiting

Address

Children's Hospital of Wisconsin

Milwaukee, Wisconsin, 53226

Site Contact

Site Public Contact

MACCCTO@mcw.edu

414-955-4727

International Sites

IWK Health Centre, Halifax, Nova Scotia, Canada

Status

Recruiting

Address

IWK Health Centre

Halifax, Nova Scotia, B3K 6R8

Site Contact

Site Public Contact

Research@iwk.nshealth.ca

902-470-8037

HIMA San Pablo Oncologic Hospital, Caguas, Puerto Rico

Status

Recruiting

Address

HIMA San Pablo Oncologic Hospital

Caguas, , 00726

Site Contact

Site Public Contact

787-653-3434